This Phase 1/2 open-label study will combine methods for conducting MDMA-assisted
psychotherapy with methods from the CBCT for PTSD in order to treat 10 participants with
chronic PTSD and their partners (intimate or non-intimate significant other who does not have
a current diagnosis of PTSD) in order to explore whether combined treatment is effective.
Each therapy team will have one therapist trained and experienced in MDMA assisted
psychotherapy and one therapist trained and experienced in CBCT. During the first
experimental session, both participants will receive 75 mg of MDMA followed 1.5 to 2 hours
later by an optional supplemental half-dose of 37.5 mg. During the second experimental
session, an initial dose of either 100 or 75 mg of MDMA will be administered to both
participants followed by an optional supplemental half-dose of either 50 mg or 37.5 mg. The
primary objective of this study is to assess changes in PTSD symptoms from Baseline to
Primary Endpoint in CAPS-5 total severity scores in PTSD participants.